Erenumab Offers Relief for MOH in Chronic Migraine

Erenumab, injected monthly at 140 mg, effectively induces remission of nonopioid medication overuse headache (MOH) in patients with chronic migraine within 6 months. The treatment significantly reduces the number of acute headache medication days (AHMDs). A study of 584 adults found that 69% of those on 140 mg erenumab achieved MOH remission, compared to 53% on placebo. The average monthly AHMDs decreased in the erenumab groups compared to placebo. Erenumab was well-tolerated, with constipation and COVID-19 being the most common side effects. This finding suggests that erenumab may simplify and improve care for patients with MOH.

Source link